Wyeth-Ayerst To Produce Enbrel At Former Glaxo Wellferon Site
Executive Summary
Wyeth-Ayerst plans to manufacture the rheumatoid arthritis therapy Enbrel at a West Greenwich, R.I. biopharmaceutical facility purchased from Glaxo.
You may also be interested in...
Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity
Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.
Immunex Enbrel Sales Capped At $800 Mil. With Current Production Capacity
Sales of Immunex' rheumatoid arthritis drug Enbrel (etanercept) in the U.S. are capped at $800 mil. a year at the current manufacturing capacity, Immunex said in an Aug. 9 Securities & Exchange Commission filing.
Glaxo Manufacturing Initiative Will Yield $600 Mil. Annual Savings
Glaxo Wellcome estimates that its manufacturing streamlining initiative "will be earnings enhancing in 2000" and will generate an annual benefit of over $600 mil. (L370 mil.) per annum in 2003.